Member Info for fali41

What is the ctda protocol of approval. Any idea if its aimilar to the one we are being sued for? Can we draw comparisons?

Great find Ex and thanks for sharing. The company lawyers need to get their hands on this. This document will stand up in court all day as it highlights the governements intention for testing methods and the fact they wanted to pull out the novacyt contract but needed an excuse. Didnt meet the standards my a***. How they are going through with this stil is beyond me.

Buying in the 60’s with a mcap under £50m is a gamble considering the future revenue potential and dhsc outcome. But all things considered you could look back in a year or three and think wow that was a bargain!

K, gardening leave?

As a CEO of a public listed company. Who decides to sack him? I thought it was the shareholders?

He probably had a 12 month clause in his contract to achieve set objectives and failed on those

I wonder what has prompted this?

Quote from Professor Young

He added: “We’ve really taken our eye off the ball with Covid tests. We can only detect variants or know what’s coming by doing sequencing from PCR testing, and that’s not going on anywhere near the extent it was a year ago.”

The contract with the DHSC was awarded and the SP started motoring. What a difference a couple of years make! Where will the company be in 2 years time? The legal costs for the 6 months for dispute were nearly half a million. Thats 1/4 of our current quarterly revenue. Absolute bonkers! The DHSC must be forking out similar costs! They must be desperate to want to avoid payment as spending cuts will mean less budget for governement departments. How do they justify funding a legal claim if they dont believe they can claw back the money?

Val - thats a fair summary and if im being honest the only real negative from that rns is the revenue which on face is disastrous lets be honest. Although we need to analyse that with some context. They are developing new products which appear to be in demand and the science is good. The R&D department have proven they can deliver. If we dont start seeing growing revenues in the next year or two then i would be concerned. We still have a windfall of cash and potentially more to invest to accelerate this growth. Its hard to see the light but like my investments in the past where i sell on not believeing the future potential they prove me wrong. If i held on to only 2 of them until now i would be retired before 40! One can only hope this turns around and the strategy delivers!

Pi100 what were you expecting? The company is transitioning away from covid it is building a base for growth. Dont expect miracles in a few quarters. This will take time, organically an through M&A. If you dont believe they can then why stay invested?

As the currency dwindles at near record lows is this a good time for the DHSC to settle perhaps utilising any foreign currency conversion?

There is share loss relief but that would be for a qualifying trading company. Nova dont qualify as they dont meet the conditions and also thr shares were purchased and not subscribed for. Therefore the capital loss cannot be offset against general income

Approval of the product apparently the DHSC want £130m for?? What is actually going on with this dispute? It doesnt make any sense!

Lots going on behind the scenes. Trust the process, revenue generating and cash rich with no debt. In this devasting market investors are looking for companies like this to invest. I am optimistic about the second half of this year lots to look forward to.

Nova have tweeted saying its available for sale

https://apple.news/Aut7MuwWTQLmEAcwYnFYkqg

https://www.independent.co.uk/news/health/covid-test-rosalind-franklin-laboratory-b2057988.html

When you spend ridiculous amounts on such projects that become redundant to use you need to claw back the money someway!

Captain, what are you not getting? The more the company keep the lid on the dispute details within the piblic domain the less likely a competitor approaches or even attempts a hostile takeover due to the uncertainty. The fact they have now raised a claim for £134m enforced this point further.

Also, they do want to bring in II’s and judging by the comprehensiveness of the presentation i cannot see why some risk averse funds dont take a starter position here at £110 mcap. Potentially, some sharks like BIO may be onnthe prowl aswel. The strengths of this business have always been thr R&D and judging by the development of the covid assays i would bet they develop some really good non-covid ones. Also a key nugget was the M&A could actually increase the timescales for achieving £100m and infact exceed that target.